Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

2.

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.

Dong H, Chen L, Chen X, Gu H, Gao G, Gao Y, Dong B.

Leuk Lymphoma. 2009 Jun;50(6):974-84. doi: 10.1080/10428190902895780.

PMID:
19391038
3.

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.

J Clin Oncol. 2009 Apr 10;27(11):1788-93. doi: 10.1200/JCO.2008.18.8573. Epub 2009 Mar 9.

PMID:
19273705
4.

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S.

Am J Hematol. 2009 Jan;84(1):6-14. doi: 10.1002/ajh.21310.

5.

From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.

Colvin LA, Johnson PR, Mitchell R, Fleetwood-Walker SM, Fallon M.

J Clin Oncol. 2008 Sep 20;26(27):4519-20. doi: 10.1200/JCO.2008.18.5017. No abstract available.

PMID:
18802169
6.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators.

N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.

7.

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG.

J Clin Oncol. 2008 Oct 10;26(29):4784-90. doi: 10.1200/JCO.2007.14.9641. Epub 2008 Aug 18.

PMID:
18711175
8.

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Argyriou AA, Iconomou G, Kalofonos HP.

Blood. 2008 Sep 1;112(5):1593-9. doi: 10.1182/blood-2008-04-149385. Epub 2008 Jun 23. Review. Erratum in: Blood. 2009 Apr 30;113(18):4478.

9.

Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Smith LC, Bertolotti P, Curran K, Jenkins B; IMF Nurse Leadership Board.

Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):37-52. doi: 10.1188/08.CJON.S1.37-51.

10.

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B.

Leukemia. 2008 Jul;22(7):1419-27. doi: 10.1038/leu.2008.99. Epub 2008 Apr 24.

11.

Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.

Neznanov N, Dragunsky EM, Chumakov KM, Neznanova L, Wek RC, Gudkov AV, Banerjee AK.

PLoS One. 2008 Apr 2;3(4):e1887. doi: 10.1371/journal.pone.0001887.

12.

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, Caravita T, Morabito F, Magarotto V, Ruggeri M, Avonto I, Musto P, Cascavilla N, Bruno B, Boccadoro M.

Ann Oncol. 2008 Jun;19(6):1160-5. doi: 10.1093/annonc/mdn018. Epub 2008 Mar 6.

PMID:
18326520
13.

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.

Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D.

Leuk Lymphoma. 2008 Mar;49(3):502-7. doi: 10.1080/10428190701817258.

PMID:
18297527
14.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

15.

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD.

Haematologica. 2008 Feb;93(2):295-8. doi: 10.3324/haematol.11627.

16.

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.

Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT.

J Clin Invest. 2008 Feb;118(2):491-504. doi: 10.1172/JCI33102.

17.

Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.

Maseda D, Meister S, Neubert K, Herrmann M, Voll RE.

Cell Death Differ. 2008 Mar;15(3):600-12. doi: 10.1038/sj.cdd.4402297. Epub 2008 Jan 11.

18.

The pharmacologic management of cancer pain.

Cleary JF.

J Palliat Med. 2007 Dec;10(6):1369-94. Review.

PMID:
18095817
19.

Bortezomib-induced peripheral neurotoxicity: still far from a painless gain.

Cavaletti G, Nobile-Orazio E.

Haematologica. 2007 Oct;92(10):1308-10. No abstract available.

20.

Pathophysiology of multiple myeloma bone disease.

Lentzsch S, Ehrlich LA, Roodman GD.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1035-49, viii. Review.

PMID:
17996587

Supplemental Content

Support Center